When new areas of enhancement are identified, our surgeons and neuro-oncologists want to see IB’s Delta T1 and rCBV on our glioma patients to guide therapeutic and surgical management. The additional information added by IB’s rCBV mapping to conventional imaging is instrumental in patient management.

I really enjoyed working with IB Neuro and the other plugins; it is very user-friendly and just beautifully made! And thank you for all your help and advice. I really appreciated it and very much liked working with you!

The T1 with contrast is hard to interpret, but I think the Delta T1 says it all.

We appreciate the speed of IB products and their compatibility with PACS. More recently, we have started to use IB products for image-guided surgical planning. We anticipate their use for radiation therapy planning in the near future. Our Neurosurgeons, Radiation Oncologists and Neuro-Oncologists find perfusion scans and delta T1 maps of the brain to be very useful, and now routinely write orders to obtain this information.

I have found the IB Neuro plugin to be a robust, accurate implementation of CBV algorithms cited in the literature. It is easy to use, and meshes nicely with our platform. We have found normalized CBV maps overlayed on contrast enhanced or FLAIR images to be very useful for brain tumor analysis and follow-up.

During image analysis, various factors can lead to incorrect interpretation. For example, T1 hyperintense signals, such as those seen in subacute hemorrhage or protein-rich contents, can make it difficult to assess contrast enhancement.
Standard subtraction methods are often limited by misalignment or the lack of signal standardization between pre- and post-contrast images. The dT1 method addresses these issues by introducing a standardization step before coregistration, resulting in high-quality, quantifiable images. This improves reliability in clinically relevant situations such as assessing residual enhancing tumor after surgery, differentiating sellar lesions, and evaluating subtle enhancement in complex cases.

I have been using Imaging Biometrics software for 10 years and have consistently found their advanced, quantitatively driven imaging solutions to be scientifically validated and uniquely informative in the assessment of brain tumours. Their products provide valuable insights that help answer challenging questions in neuro-oncology and have proven highly beneficial in both diagnosing and monitoring treatment in brain tumour patients.